[VIRTUAL] SEQUENTIAL TREATMENT WITH SORAFENIB FOLLOWED BY REGORAFENIB IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC): INTERIM ANALYSIS OF THE OBSERVATIONAL REFINE STUDY

[VIRTUAL] RAMUCIRUMAB FOR PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA AND ELEVATED ALPHA FETOPROTEIN FOLLOWING A NON-SORAFENIB BASED SYSTEMIC THERAPY: INTERIM RESULTS FROM AN EXPANSION COHORT OF THE PHASE 3 REACH-2 STUDY

[VIRTUAL] OUTCOMES FOR PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA AND CHILD-PUGH B LIVER FUNCTION IN THE PHASE 3 CELESTIAL STUDY OF CABOZANTINIB VERSUS PLACEBO

[VIRTUAL] POSTPROGRESSION SURVIVAL AFTER LENVATINIB TREATMENT FOR ADVANCED HEPATOCELLULAR CARCINOMA

[VIRTUAL] EXPOSURE-RESPONSE ANALYSIS FOR NIVOLUMAB + IPILIMUMAB COMBINATION THERAPY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA

[VIRTUAL] SORAFENIB (SOR) COMBINED WITH NIVOLUMAB (NIVO) IN ADVANCED HEPATOCELLULAR CARCINOMA (HCC): SAFETY AND EFFICACY IN A DOSE ESCALATION COHORT

[VIRTUAL] EFFICACY AND SAFETY OF LENVATINIB AS A SALVAGE THERAPY OF TRANSARTERIAL TREATMENT FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA

[VIRTUAL] EFFECT OF PEMBROLIZUMAB (PEMBRO) ON HEPATITIS B VIRUS (HBV) LOAD AND AMINOTRANSFERASE (ALT) LEVELS IN PATIENTS (PTS) WITH ADVANCED HEPATOCELLULAR CARCINOMA (AHCC) IN KEYNOTE-224 AND KEYNOTE-240

[VIRTUAL] ALPHA-FETOPROTEIN (AFP) KINETICS AS A POTENTIAL SURROGATE BIOMARKER IN PATIENTS (PTS) WITH HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH ATEZOLIZUMAB (ATEZO) + BEVACIZUMAB (BEV)

[VIRTUAL] PROTON BEAM RADIOTHERAPY VERSUS RADIOFREQUENCY ABLATION TREATMENT IN PATIENTS WITH RECURRENT HEPATOCELLULAR CARCINOMA: A RANDOMIZED CONTROLLED PHASE 3 NON-INFERIORITY APROH TRIAL

[VIRTUAL] RADIOLOGICAL AND PATHOLOGICAL RESPONSE TO NEOADJUVANT NIVOLUMAB IN PATIENTS WITH BCLC A HCC TREATED BY CURATIVE PERCUTANEOUS IRREVERSIBLE ELECTROPORATION: PRELIMINARY REPORT FROM THE FRENCH MULTICENTRE PHASE 2 NIVOLEP TRIAL.

[VIRTUAL] THE NOVEL REGIMEN OF TREMELIMUMAB IN COMBINATION WITH DURVALUMAB PROVIDES A FAVORABLE SAFETY PROFILE AND CLINICAL ACTIVITY FOR PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (AHCC)

[VIRTUAL] PEMBROLIZUMAB IN COMBINATION WITH GEMCITABINE AND CISPLATIN FOR THE TREATMENT OF ADVANCED BILIARY TRACT CANCER: PHASE 3 KEYNOTE-966 TRIAL IN PROGRESS

[VIRTUAL] LEAP-012: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF PEMBROLIZUMAB PLUS LENVATINIB IN COMBINATION WITH TRANSARTERIAL CHEMOEMBOLIZATION (TACE) IN PATIENTS WITH INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA (HCC) NOT AMENABLE TO CURATIVE TREATMENT

[VIRTUAL] A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF TRANSARTERIAL CHEMOEMBOLIZATION COMBINED WITH CONCURRENT DURVALUMAB FOLLOWED BY DURVALUMAB OR DURVALUMAB PLUS BEVACIZUMAB THERAPY IN PATIENTS WITH LOCOREGIONAL HEPATOCELLULAR CARCINOMA (HCC): EMERALD-1